 <h1>Ponatinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of ponatinib include:</b> arterial thrombosis, venous thrombosis, cardiac failure, congestive heart failure, pleural effusion, bone marrow depression, conjunctival irritation, dizziness, dyspnea, eye pain, fluid retention, gastrointestinal hemorrhage, headache, hyperesthesia, hypertension, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum lipase, paresthesia, peripheral edema, peripheral neuropathy, and xerophthalmia. <b>Other side effects include:</b> acute myocardial infarction, pancreatitis, severe bone marrow depression, supraventricular tachycardia, blurred vision, coronary artery disease, hemorrhage, hyperuricemia, and tachyarrhythmia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ponatinib: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Arterial occlusions have occurred in at least 35% of ponatinib hydrochloride-treated patients, including fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Some patients experienced more than 1 type of event. Patients experienced these events with and without cardiovascular risk factors, including patients less than 50 years of age. Venous occlusive events have occurred in 6% of ponatinib-treated patients. Monitor for evidence of arterial occlusion and venous thromboembolism; interrupt or stop ponatinib hydrochloride immediately for arterial occlusion and consider dose modification or discontinuation for serious venous thromboembolism. Heart failure, including fatalities, occurred in 9% of ponatinib hydrochloride-treated patients. Monitor cardiac function; interrupt or stop ponatinib hydrochloride for new or worsening heart failure. Hepatotoxicity, liver failure, and death have occurred with ponatinib hydrochloride treatment. Monitor hepatic function; interruption may be necessary if hepatotoxicity is suspected.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ponatinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking ponatinib:</p><p>
<i>More common</i>
</p><ul>
<li>Bladder pain</li>
<li>bleeding gums</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>blurred vision</li>
<li>chest pain</li>
<li>chills</li>
<li>cloudy urine</li>
<li>confusion</li>
<li>constipation</li>
<li>cough or hoarseness</li>
<li>coughing up blood</li>
<li>decreased urine output</li>
<li>difficult, burning, or painful urination</li>
<li>difficulty with breathing or swallowing</li>
<li>dilated neck veins</li>
<li>dizziness</li>
<li>extreme fatigue</li>
<li>fainting</li>
<li>frequent urge to urinate</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>indigestion</li>
<li>irregular breathing</li>
<li>joint pain, stiffness, or swelling</li>
<li>lightheadedness</li>
<li>lower back, side, or stomach pain</li>
<li>nervousness</li>
<li>nosebleeds</li>
<li>pains in the chest, groin, or legs, especially calves of the legs</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>pale skin</li>
<li>paralysis</li>
<li>pinpoint red spots on the skin</li>
<li>pounding in the ears</li>
<li>prolonged bleeding from cuts</li>
<li>rapid weight gain</li>
<li>rapid, shallow breathing</li>
<li>red or black, tarry stools</li>
<li>red or dark brown urine</li>
<li>severe headaches of sudden onset</li>
<li>slow or fast heartbeat</li>
<li>sore throat</li>
<li>sudden loss of coordination</li>
<li>sudden shortness of breath</li>
<li>sudden slurred speech</li>
<li>sudden vision changes</li>
<li>tingling of the hands or feet</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual weight gain or loss</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>burning, numbness, tingling, or painful sensations</li>
<li>chest pain or discomfort</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>pain, redness, or swelling in the arms or legs</li>
<li>sudden shortness of breath</li>
<li>unsteadiness or awkwardness</li>
<li>weakness in the arms, hands, legs, or feet</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Abdominal or stomach cramps or tenderness</li>
<li>blue-green halos seen around objects</li>
<li>clay-colored stools</li>
<li>dark urine</li>
<li>decreased appetite</li>
<li>diarrhea</li>
<li>dry eyes</li>
<li>fever</li>
<li>headache</li>
<li>itching or skin rash</li>
<li>loss of appetite</li>
<li>nausea and vomiting</li>
<li>sensitivity of the eyes to light</li>
<li>severe vomiting, sometimes with blood</li>
<li>unusual tiredness or weakness</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ponatinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back or bone pain</li>
<li>cracked lips</li>
<li>difficulty having a bowel movement (stool)</li>
<li>difficulty with moving</li>
<li>dry skin</li>
<li>itching, pain, redness, swelling, tenderness, or warmth on the skin</li>
<li>lack or loss of strength</li>
<li>muscle aches</li>
<li>muscle pain or stiffness</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
<li>trouble sleeping</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ponatinib: oral tablet</i></p><h3>General</h3><p>-A safety analysis showed a significant increase in grade 3 or greater adverse reactions (thrombocytopenia, neutropenia, rash, elevated ALT/AST, pancreatitis, elevated lipase) with an increase in dose intensity.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>-Very common (10% or more): Hypertension (74%), elevated blood pressure (68%), arterial ischemia (42%), arterial occlusion (35%), hemorrhage (28%), arrhythmia (19%), heart failure/left ventricular dysfunction (15%) </p>
<p>-Common (1% to 10%): Venous thromboembolism, atrial fibrillation, myocardial infarction, myocardial ischemia, congestive cardiac failure, coronary artery disease, angina pectoris, decreased ejection fraction, acute coronary syndrome, atrial flutter, peripheral arterial occlusive disease, peripheral ischemia, peripheral artery stenosis, intermittent claudication, deep vein thrombosis, hot flush, flushing, palpitations, poor peripheral circulation, splenic infarction</p>
<p>-Uncommon (0.1% to 1%): Hypertensive crisis, renal artery stenosis, cardiac discomfort</p>
<p><b>Frequency not reported</b>: Ischemic cardiomyopathy, coronary arteriospasm<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>-Very common (10% or more): Rash and related conditions (63%), dry skin (42%), pruritus (13%), alopecia (11%), cellulitis (11%), erythema (10%) </p>
<p>-Common (1% to 10%): Folliculitis, skin exfoliation, night sweats, hyperhidrosis, petechia, ecchymosis, skin pain, exfoliative dermatitis, hyperkeratosis, skin hyperpigmentation<sup>[Ref]</sup></p><h3>Hematologic</h3><p>-Very common (10% or more): Leukopenia (63%), myelosuppression (59%), neutropenia (59%), febrile neutropenia (25%), anemia (52%), thrombocytopenia (49%), lymphopenia (32%)</p>
<p>-Common (1% to 10%): Pancytopenia<sup>[Ref]</sup></p><h3>Endocrine</h3><p>-Very common (10% or more): Increased glucose (54%), decreased glucose (13%)</p>
<p>-Common (1% to 10%): Hypothyroidism<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>-Very common (10% or more): Constipation (53%), abdominal pain (48%), increased lipase (42%), nausea (34%), diarrhea (29%), vomiting (27%), oral mucositis (23%), increased amylase (18%)</p>
<p>-Common (1% to 10%): GI hemorrhage, pancreatitis, gastroesophageal reflux disease, stomatitis, dyspepsia, abdominal distention, abdominal discomfort, dry mouth</p>
<p>-Frequency not reported: GI fistula, GI perforation<sup>[Ref]</sup></p><h3>Other</h3><p>-Very common (10% or more): Asthenia/fatigue (49%), pyrexia (40%), peripheral edema (25%), pain (60%), chills (13%), sepsis (13%)  </p>
<p>-Common (1% to 10%): Effusions (pericardial, pleural, ascites), influenza-like illness, peripheral swelling, non-cardiac chest pain, face edema, malaise<sup>[Ref]</sup></p><h3>Nervous system</h3><p>-Very common (10% or more): Headache (43%), peripheral neuropathy (24%), dizziness (16%)</p>
<p>-Common (1% to 10%): Cranial neuropathy, cerebrovascular accident, cerebral infarction, lethargy, migraine, hyperesthesia, hypoesthesia, paresthesia, transient ischemic attack</p>
<p>-Uncommon (0.1% to 1%): Cerebral artery stenosis, cerebral hemorrhage, intracranial hemorrhage</p>
<p>-Postmarketing reports: Reversible posterior leukoencephalopathy syndrome/posterior reversible encephalopathy syndrome (RPLS/PRES)<sup>[Ref]</sup></p><h3>Hepatic</h3><p>-Very common (10% or more): Increased ALT (41%), increased alkaline phosphatase (40%), increased AST (35%), hepatotoxicity (29%), decreased albumin (27%), increased bilirubin (13%)</p>
<p>-Common (1% to 10%): Increased gamma-glutamyltransferase </p>
<p>-Uncommon (0.1% to 1%): Hepatic failure, jaundice</p>
<p>-Frequency not reported: Acute liver failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p>-Very common (10% or more): Decreased phosphorus (33%), decreased calcium (30%), decreased appetite (31%), fluid retention (31%), decreased sodium (27%), increased creatinine (21%), decreased bicarbonate (19%), increased potassium (19%), decreased potassium (18%), decreased weight (13%), increased calcium (12%), increased sodium (10%)   </p>
<p>-Common (1% to 10%): Hypertriglyceridemia, dehydration, increased blood cholesterol</p>
<p>-Uncommon (0.1% to 1%): Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>-Very common (10% or more): Arthralgia (33%), myalgia (24%), pain in extremity (23%), back pain (21%), bone pain (14%), muscle spasms (14%), musculoskeletal pain (11%)</p>
<p>-Common (1% to 10%): Neck pain, musculoskeletal chest pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p>-Very common (10% or more): Cough (22%), dyspnea (20%), pleural effusion (19%), nasopharyngitis (18%), pneumonia (16%), upper respiratory tract infection (14%) </p>
<p>-Common (1% to 10%): Epistaxis, dysphonia, pulmonary hypertension, pulmonary embolism<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>-Very common (10% or more): Urinary tract infection (14%) </p>
<p>-Common (1% to 10%): Hyperuricemia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>-Very common (10% or more): Insomnia (13%)</p>
<p>-Common (1% to 10%): Confusional state, erectile dysfunction<sup>[Ref]</sup></p><h3>Ocular</h3><p>-Very common (10% or more): Ocular toxicities (14%; conjunctival irritation, corneal erosion/abrasion, dry eye, conjunctivitis, conjunctival hemorrhage, hyperemia, eye pain)</p>
<p>-Common (1% to 10%): Blurred vision, periorbital edema, eyelid edema, visual impairment, retinal toxicities (macular edema, retinal vein occlusion/thrombosis, retinal artery occlusion, retinal hemorrhage)</p>
<p>-Uncommon (0.1% to 1%): Vision loss<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Iclusig (ponatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about ponatinib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: BCR-ABL tyrosine kinase inhibitors</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ponatinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Iclusig</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
<li>Chronic Myelogenous Leukemia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ponatinib: oral tablet</i></p><h3>General</h3><p>-A safety analysis showed a significant increase in grade 3 or greater adverse reactions (thrombocytopenia, neutropenia, rash, elevated ALT/AST, pancreatitis, elevated lipase) with an increase in dose intensity.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>-Very common (10% or more): Hypertension (74%), elevated blood pressure (68%), arterial ischemia (42%), arterial occlusion (35%), hemorrhage (28%), arrhythmia (19%), heart failure/left ventricular dysfunction (15%) </p><p>-Common (1% to 10%): Venous thromboembolism, atrial fibrillation, myocardial infarction, myocardial ischemia, congestive cardiac failure, coronary artery disease, angina pectoris, decreased ejection fraction, acute coronary syndrome, atrial flutter, peripheral arterial occlusive disease, peripheral ischemia, peripheral artery stenosis, intermittent claudication, deep vein thrombosis, hot flush, flushing, palpitations, poor peripheral circulation, splenic infarction</p><p>-Uncommon (0.1% to 1%): Hypertensive crisis, renal artery stenosis, cardiac discomfort</p><p><b>Frequency not reported</b>: Ischemic cardiomyopathy, coronary arteriospasm<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>-Very common (10% or more): Rash and related conditions (63%), dry skin (42%), pruritus (13%), alopecia (11%), cellulitis (11%), erythema (10%) </p><p>-Common (1% to 10%): Folliculitis, skin exfoliation, night sweats, hyperhidrosis, petechia, ecchymosis, skin pain, exfoliative dermatitis, hyperkeratosis, skin hyperpigmentation<sup>[Ref]</sup></p><h3>Hematologic</h3><p>-Very common (10% or more): Leukopenia (63%), myelosuppression (59%), neutropenia (59%), febrile neutropenia (25%), anemia (52%), thrombocytopenia (49%), lymphopenia (32%)</p><p>-Common (1% to 10%): Pancytopenia<sup>[Ref]</sup></p><h3>Endocrine</h3><p>-Very common (10% or more): Increased glucose (54%), decreased glucose (13%)</p><p>-Common (1% to 10%): Hypothyroidism<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>-Very common (10% or more): Constipation (53%), abdominal pain (48%), increased lipase (42%), nausea (34%), diarrhea (29%), vomiting (27%), oral mucositis (23%), increased amylase (18%)</p><p>-Common (1% to 10%): GI hemorrhage, pancreatitis, gastroesophageal reflux disease, stomatitis, dyspepsia, abdominal distention, abdominal discomfort, dry mouth</p><p>-Frequency not reported: GI fistula, GI perforation<sup>[Ref]</sup></p><h3>Other</h3><p>-Very common (10% or more): Asthenia/fatigue (49%), pyrexia (40%), peripheral edema (25%), pain (60%), chills (13%), sepsis (13%)  </p><p>-Common (1% to 10%): Effusions (pericardial, pleural, ascites), influenza-like illness, peripheral swelling, non-cardiac chest pain, face edema, malaise<sup>[Ref]</sup></p><h3>Nervous system</h3><p>-Very common (10% or more): Headache (43%), peripheral neuropathy (24%), dizziness (16%)</p><p>-Common (1% to 10%): Cranial neuropathy, cerebrovascular accident, cerebral infarction, lethargy, migraine, hyperesthesia, hypoesthesia, paresthesia, transient ischemic attack</p><p>-Uncommon (0.1% to 1%): Cerebral artery stenosis, cerebral hemorrhage, intracranial hemorrhage</p><p>-Postmarketing reports: Reversible posterior leukoencephalopathy syndrome/posterior reversible encephalopathy syndrome (RPLS/PRES)<sup>[Ref]</sup></p><h3>Hepatic</h3><p>-Very common (10% or more): Increased ALT (41%), increased alkaline phosphatase (40%), increased AST (35%), hepatotoxicity (29%), decreased albumin (27%), increased bilirubin (13%)</p><p>-Common (1% to 10%): Increased gamma-glutamyltransferase </p><p>-Uncommon (0.1% to 1%): Hepatic failure, jaundice</p><p>-Frequency not reported: Acute liver failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p>-Very common (10% or more): Decreased phosphorus (33%), decreased calcium (30%), decreased appetite (31%), fluid retention (31%), decreased sodium (27%), increased creatinine (21%), decreased bicarbonate (19%), increased potassium (19%), decreased potassium (18%), decreased weight (13%), increased calcium (12%), increased sodium (10%)   </p><p>-Common (1% to 10%): Hypertriglyceridemia, dehydration, increased blood cholesterol</p><p>-Uncommon (0.1% to 1%): Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>-Very common (10% or more): Arthralgia (33%), myalgia (24%), pain in extremity (23%), back pain (21%), bone pain (14%), muscle spasms (14%), musculoskeletal pain (11%)</p><p>-Common (1% to 10%): Neck pain, musculoskeletal chest pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p>-Very common (10% or more): Cough (22%), dyspnea (20%), pleural effusion (19%), nasopharyngitis (18%), pneumonia (16%), upper respiratory tract infection (14%) </p><p>-Common (1% to 10%): Epistaxis, dysphonia, pulmonary hypertension, pulmonary embolism<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>-Very common (10% or more): Urinary tract infection (14%) </p><p>-Common (1% to 10%): Hyperuricemia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>-Very common (10% or more): Insomnia (13%)</p><p>-Common (1% to 10%): Confusional state, erectile dysfunction<sup>[Ref]</sup></p><h3>Ocular</h3><p>-Very common (10% or more): Ocular toxicities (14%; conjunctival irritation, corneal erosion/abrasion, dry eye, conjunctivitis, conjunctival hemorrhage, hyperemia, eye pain)</p><p>-Common (1% to 10%): Blurred vision, periorbital edema, eyelid edema, visual impairment, retinal toxicities (macular edema, retinal vein occlusion/thrombosis, retinal artery occlusion, retinal hemorrhage)</p><p>-Uncommon (0.1% to 1%): Vision loss<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Iclusig (ponatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA. </p><h2>More about ponatinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: BCR-ABL tyrosine kinase inhibitors</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ponatinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
<li>Chronic Myelogenous Leukemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>